Slingshot members are tracking this event:

GlycoMimetics to Release Phase 1/2 Data for GMI-1271 for Reducing Chemotherapy Resistance and Enriching T-Cells

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Currently, the GMI-1271 drug being developed by GlycoMimetics is in the Phase 1/2 trial.  The Company expects the data from the trial to be released in Q2 of 2016.  The drug is to be used in combination with chemotherapy for the treatment of acute myeloid leukemia (AML).  The Company also announced that when "used in combination with G-CSF (filgrastim) to mobilize and enrich progenitor T cells known as T memory stem (Tscm) and T central memory (Tcm) cells, which provide improved reconstitution and persistence".  
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 10, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Gmi-1271, Chemotherapy Resistance, Phase 1/2 Data, T-cells